Promene nivoa metabolita sfingolipida u serumu pacijenata kod lokalno uznapredovalog karcinoma rektuma: pilot studija

  • Jasna Bjelanovic Center for medical biochemistry, University Clinical center of Serbia
  • Aleksandra Nikolić Institute of Molecular Genetics and Genetic Engeneering, University of Belgrade
  • Mutay Aslan Department of Biochemistry, Akdeniz University Medical Faculty, Antalya, Turkey
  • Marko Miladinov Clinic for Digestive Surgery-First Surgical Clinic, University clinical center of Serbia, Belgrade, Serbia
  • Nikola Kotur Institute of Molecular Genetics and Genetic Engeneering, University of Belgrade
  • Goran Barišić Clinic for Digestive Surgery-First Surgical Clinic, University clinical center of Serbia, Belgrade, Serbia: Faculty of Medicine, University of Belgrdae, Serbia
  • Sandra Dragićević Institute of Molecular Genetics and Genetic Engeneering, University of Belgrade
DOI: https://doi.org/10.5937/jomb0-55113

Sažetak


Sažetak

Uvod: Promene u nivou sfingolipida mogu da doprinesu nastanku karcinoma rektuma, progresiji bolesti i odgovoru na terapiju usled njihove regulacije različitih bioloških procesa uključujući apoptozu. Cilj ove studije je bio da se analizira profil sfingolipida u serumu kod pacijenata sa karcinomom rektuma i da se ispita njegova povezanost sa apoptotskim statusom tkiva tumora i odgovorom na terapiju.

Metode: Nivo ceramida (CER) i sfingomijelina (SM) je analiziran u serumu kod 22 pacijenta sa lokalno uznapredovalim karcinomom rektuma i kod 24 zdrave osobe pomoću ultrabrze tečne hromatografije kombinovane sa tandem masenom spektrometrijom. Ekspresija proapoptotskog gena BAX (BCL2 asocirjaući X, regulator apoptoze) i antiapoptotskog gena BCL2 (BCL2 regulator apoptoze) je analizirana pomoću metode kvantitativni PCR u realnom vremenu u uzorcima tumorskog tkiva i zdrave crevne sluznice kod pacijenata.

Rezultati: Nivoi C18 CER, C22 CER, C24 CER, C18 SM i C24 SM su bili značajno niži u serumu pacijenata u odnosu na kontrolnu grupu (P<0,05). Za C20 CER, C22 CER i C24 CER je utvr|ena pozitivna korelacija sa pro-apoptotskim statusom tumorskog tkiva (r=0,619, P=0,018; r=0,694, P=0,006 i r=0,601, P=0,023, respektivno). Nije pronađena razlika u nivoima sfingolipida u serumu između pacijenata sa dobrim, umerenim i lošim odgovorom na terapiju.

Zaključak: Ovi rezultati pokazuju povezanost sfingolipida sa karcinomom rektuma. Međutim, neophodna su dalja istraživanja koja bi obuhvatila veći broj ispitanika kako bi se razjasnila povezanost sfingolipidnih metabolita sa odgovorom na terapiju.

 

Ključne reči: apoptoza, neoadjuvantna hemioradioterapija, karcinom rektuma, sfingolipidi

Objavljeno
2025/02/06
Broj časopisa
Vol. 44 Br. 3 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Jasna Bjelanovic

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.